Aug 20 (Reuters) - Rocket Pharmaceuticals Inc RCKT.O:
ROCKET PHARMACEUTICALS ANNOUNCES FDA HAS LIFTED THE CLINICAL HOLD ON THE PIVOTAL PHASE 2 TRIAL OF RP-A501 FOR THE TREATMENT OF DANON DISEASE
ROCKET PHARMACEUTICALS INC - FDA AUTHORIZES STUDY RESUMPTION WITH RECALIBRATED DOSE
ROCKET PHARMACEUTICALS- TO WORK WITH INVESTIGATORS TO IMPLEMENT IMMUNOMODULATORY REGIMEN MORE CLOSELY REFLECTING GIVEN IN PHASE 1 PEDIATRIC COHORT